Sequence: WEAKLAKALAKALAKHLAKALAKALKA
| Experiment Id | EXP000867 |
|---|---|
| Paper | Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold |
| Peptide | KALA |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | medium |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | |
| Formulation Format | lipoplex (ionizable lipid LNP + CPP + mRNA), ex vivo DC vaccine |
| Formulation Components | Main lipid ssPalmM; DOPE; cholesterol (3:4:3 molar). Surface peptide STR-KALA. BMDCs transfected ex vivo then injected. |
| Size Nm | 92.00 |
| Zeta Mv | 24.00 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | BMDCs transfected ex vivo |
| Animal Model | C57BL/6 mice; in vivo CTL assay (CFSEhigh/low splenocytes) |
| Administration Route | footpad (BMDC vaccination); IV injection of CFSE-labeled target/control splenocytes |
| Output Type | OVA-specific CTL activity (% lysis) |
| Output Value | ~6% lysis |
| Output Units | |
| Output Notes | Mice immunized with BMDCs transfected with OVA-mRNA; CTL assessed 7 days post-immunization (Fig. 8). |
| Toxicity Notes | |
| Curation Notes |